In November 2026, the FDA sent out a Drug Safety Communication, “FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition” that some drug safety observers would say was overdue. For example, this recent Drug Injury Law article about NAION side-effect warnings: “NAION With Ozempic, Wegovy, Mounjaro, or Zepbound Use: Why Are There Still No Warnings?”
So what is the FDA doing by (finally) ordering pharmaceutical companies to add NAION side-effect warnings for Wegovy (semaglutide), Mounjaro (tirzepatide), and other GLP-1 drugs (also known as GLP-1 RAs)?
From the November 9, 2026 FDA Drug Safety Communication:
The agency is requiring application holders for all GLP-1 RA medications to add information to the Warnings and Precautions section of labeling about the potential increased risk of NAION associated with use of these medications….
NAION cases have been reported for all currently marketed GLP-1 RA products. FDA concluded that there is a potential increased risk of rare NAION events in patients taking GLP-1 RAs. Based on these findings, FDA is requiring that application holders add information about the risk for NAION to the Warnings and Precautions section of labeling of all GLP-1 RAs.
We had been writing about the lack of NAION side-effect warnings and related subjects regularly on our Drug Injury Watch website, as seen by this list of nine (9) other articles from earlier this year, 2026:
- Mounjaro, Ozempic Vision Loss Lawsuits Filings Increase – 2026 News Reports
- NAION Cases Filed in Courts for Vision Loss Legal Compensation
- Ozempic Eye Side Effect NAION Warnings Update July 2026
- Semaglutide NAION Lawsuits in 2026 for Wegovy, Rybelsus, Ozempic Vision Loss
- NAION Linked To Zepbound, Mounjaro, Ozempic, Wegovy: 2026 News Update
- Ozempic and Wegovy NAION Study 2026 Report: Two New Findings
- Ozempic-NAION Warnings Should Be In January 2026 Drug Label For New Pill Version
- Ozempic NAION Risk 200% Higher Than Some Other Diabetes Drugs
- Mounjaro and Ozempic NAION Vision Loss Lawsuits: Federal Court MDL No. 3163
We have been writing about the medical and legal aspects of NAION side-effect warnings since July 2024, starting with this article: “Ozempic Side Effects Include Eye Problems With Possible Vision Loss“.
As seen above, drug injury lawsuits have been filed for people diagnosed with NAION while using Wegovy, Ozempic, or Rybelsus — all of which are semaglutide-containing drugs — as well as people who were using Mounjaro or Zepbound — both of which are tirzepatide-containing drugs. These cases seek legal compensation for vision loss and point to the responsible pharmaceutical companies’ failure to provide NAION side-effect warnings (until the FDA finally ordered them to do so in November 2026).
A person who used “brand name” semaglutide-containing drugs (Wegovy, Ozempic, Rybelsus) or tirzepatide-containing drugs (Mounjaro, Zepbound) and was diagnosed with NAION may want to file a drug injury lawsuit to get legal compensation for their vision loss. We will review your possible case free of charge, confidentially, and without any commitment to us:
Ozempic / Wegovy / Rybelsus Vision Loss Case Evaluation Form
Zepbound / Mounjaro Eye Side Effect NAION Case Evaluation Form
Other ways to have your case reviewed by attorney Tom Lamb: Email him at TJL@LambLawOffice.com, or call him at 910-256-2971.
Of course, we will watch for legal developments related to the prior failure to provide NAION side-effect warnings by the drug companies for drug injury lawsuits filed on behalf of people diagnosed with NAION while using Wegovy, Ozempic, or Rybelsus, as well as Mounjaro or Zepbound.
Mounjaro / Zepbound
Free Case Evaluation
Strictly Confidential, No Obligation
Wegovy / Ozempic / Rybelsus
Free Case Evaluation
Strictly Confidential, No Obligation